ArticleFrontiers in psychiatry2022
Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders.
Article in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Group psychedelic-assisted therapy for mental health conditions: a mixed-methods systematic review.Frontiers in public health · 2026Pooled it
- Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Pooled it
- Trial
- Development of the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET): a Delphi study.BMJ open · 2026Article
- The helioscope effect: A new framework for evaluating trauma-related memory processing in psychedelic experiences.Journal of psychopharmacology (Oxford, England) · 2026Article
- Towards social curative psychedelic treatment.Discover mental health · 2026Review
- Toward a definition of treatment-resistant posttraumatic stress disorder: A systematic review.Journal of military, veteran and family health · 2026Review
- Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico.Frontiers in public health · 2026Article
- Making a case for using MDMA-assisted psychotherapy for borderline personality disorder and complex PTSD: a descriptive systematic review of the literature.Therapeutic advances in psychopharmacology · 2026Review
- A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapy.Journal of psychopharmacology (Oxford, England) · 2026Article
- Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action.CNS drugs · 2025Review
- Evolving Psychotherapeutic Approaches for PTSD: Beyond the Fear-Based Model.Psychiatry and clinical psychopharmacology · 2025Article
- Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning-Based Advanced Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Cosmology of belonging: The role of community in the therapeutic use of psychedelics.Palliative & supportive care · 2025Article
- MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations.European child & adolescent psychiatry · 2024Review
- Psychedelics and the treatment of eating disorders: considerations for future research and practice.Journal of eating disorders · 2024Article
- Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report.Clinical case reports · 2024Article
- Methylenedioxymethamphetamine is a connectogen with empathogenic, entactogenic, and still further connective properties: It is time to reconcile "the great entactogen-empathogen debate".Journal of psychopharmacology (Oxford, England) · 2024Review
- When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research.Neuroethics · 2024Article
- The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Current neuropharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Swiss Federal Act on Narcotics allows for the restricted medical use of scheduled psychotropic drugs in cases of resistance to standard treatment, and preliminary evidence of efficacy of the scheduled drug for the particular condition. Since 2014, the authors have obtained 50 licenses on a case-by-case basis and developed a psychedelic-assisted group therapy model utilizing MDMA and LSD. The majority of the patients taking part in the psychedelic group therapy suffered from chronic complex post-traumatic stress disorder (c-PTSD), dissociative, and other post-traumatic disorders. Treatment modalities, typical developments and problems encountered during and after the psychedelic experiences are described. Recurrent depression poses a frequent problem, and requires special attention. Symptoms of c-PTSD predominantly addressed by the psychedelic experiences are the regulation of emotions and impulses, negative self-perception, alterations in relationships to others, as well as meaning, recall, and processing of traumatic memories. C-PTSD needs a larger number of psychedelic experiences in contrast to PTSD resulting from single trauma. In this model MDMA was most often used in the first phase to enhance motivation to change, strengthen the therapeutic alliance, allowing it to become more resilient, stress-relieved and less ambivalent. When emotional self-regulation, negative self-perception and structural dissociation had also begun to improve and trauma exposure was better tolerated, LSD was introduced to intensify and deepen the therapeutic process. The majority of participants improved by clinical judgement, and no serious adverse events occurred. A short case vignette describes a typical process. The experiences with this model can serve to further develop the method of psychedelic-assisted psychotherapy (PAP) and to give directions for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.